A new Horizon Europe-funded project that aims to develop a novel and promising therapy for treating gliomas.

Targeted ROS generation is a promising selective glioma treatment. However, the only current means of targeted ROS generation is photodynamic therapy (PDT), which generates ROS using photosensitisers (PS). This dependence on PS introduces various treatment limitations. GlioLighT is a Horizon Europe EIC Pathfinder Project exploring a highly novel alternative form of targeted ROS generation called Direct Light Therapy (DLT), which uses 1267nm light to directly generate ROS in cells without dependency on a PS. The principles of DLT have been demonstrated previously, but little is known about how DLT achieves its anti-cancer effects, or the extent of its therapeutic benefits. The GlioLight project aims to study and refine DLT technology, generating knowledge to improve targeted ROS generation, and bringing DLT a step closer to real world application.